Crossmark

Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma

Published Online: 2024-01-30

Authors

Iida, Keitaro

Naiki, Taku

Etani, Toshiki

Nagai, Takashi

Sugiyama, Yosuke

Isobe, Teruki

Aoki, Maria

Nozaki, Satoshi

Noda, Yusuke

Shimizu, Nobuhiko

Tomiyama, Nami

Gonda, Masakazu

Kamiya, Hiroyuki

Kubota, Hiroki

Nakane, Akihiro

Ando, Ryosuke

Kawai, Noriyasu

Yasui, Takahiro
License Information

Text and Data Mining valid from 2024-01-30

Version of Record valid from 2024-01-30
More Information

Article History

Received: 12 October 2022

Accepted: 29 January 2024

First Online: 30 January 2024

Competing interests

: The authors declare no competing interests.

Document is current